Secondary Logo

Journal Logo

UpToDate®

doi: 10.1097/01.COT.0000553129.51704.42
News
Free

UpToDate® and Oncology Times are collaborating to present select content synopses on “What's New in Oncology.” UpToDate is an evidence-based, clinical support resource used worldwide by healthcare practitioners to make decisions at the point of care. For complete, current ‘What's New’ content, or to become a subscriber for full content access, go to www.uptodate.com. “What's New” abstract information is free for all medical professionals.

Back to Top | Article Outline

Atezolizumab and Nab-Paclitaxel in Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is more immunogenic than other breast cancer subtypes and represents a promising target for immunotherapy. In the randomized IMpassion130 trial, including 900 patients with treatment-naïve metastatic TNBC, the combination of the programmed cell death ligand (PD-L1) antibody atezolizumab and nab-paclitaxel improved progression-free survival (PFS) by 1.5 months compared with nab-paclitaxel alone; however, among those with PD-L1 expressing tumors, the combination improved both PFS (7.5 versus 5.0 months) and overall survival (25 versus 15.5 months). Although some UpToDate experts advocate PD-L1 testing and the addition of atezolizumab to nab-paclitaxel in PD-L1 expressing TNBC, all acknowledge that PD-L1 testing is neither routine nor standardized in breast cancer, and that further evidence and/or regulatory approval are needed before this becomes a standard approach.

Back to Top | Article Outline

Aspirin Combined With Proton Pump Inhibitor for Patients With Barrett's Esophagus

Epidemiologic data suggest that drugs that inhibit cyclooxygenase, such as aspirin, might prevent high-grade dysplasia and esophageal cancer in patients with Barrett's esophagus. In a recent trial, over 2,500 patients with Barrett's esophagus were randomly assigned to low or high-dose esomeprazole, with or without full-dose aspirin, and were followed for a median of nine years. Compared with low-dose proton pump inhibitor (PPI) alone, aspirin combined with high-dose PPI resulted in the longest time interval to a composite endpoint (all-cause mortality, esophageal carcinoma, or high-grade dysplasia). However, the difference in event rate between aspirin and no aspirin was relatively modest and not statistically significant, and it is uncertain whether low-dose aspirin (which many patients with Barrett's esophagus use for other indications) would have a similar effect. Given these uncertainties and the potential risks associated with high-dose PPIs, we do not routinely use full-dose aspirin combined with high-dose PPI for chemoprevention or increase the PPI dose beyond what is needed for symptom control and healing of reflux esophagitis.

Back to Top | Article Outline

Chemotherapy Backbone for HER2-Overexpressing Advanced Esophagogastric Cancer

For patients with advanced human epidermal growth factor receptor 2 (HER2)-overexpressing esophagogastric adenocarcinomas, the addition of trastuzumab to cisplatin plus a fluoropyrimidine significantly improved survival in the phase III ToGA trial, although the optimal chemotherapy backbone is not established. A meta-analysis comparing different first-line trastuzumab-containing regimens in 15 published studies concluded that survival was better and treatment was less toxic when trastuzumab was combined with oxaliplatin plus a fluoropyrimidine compared with cisplatin plus a fluoropyrimidine. For most patients receiving initial trastuzumab-containing chemotherapy, an oxaliplatin/fluoropyrimidine doublet is preferred over cisplatin/fluoropyrimidine.

Back to Top | Article Outline

Hypofractionated Radiation Therapy for Early Prostate Cancer

According to new guidelines from the American Society for Radiation Oncology, the American Society of Clinical Oncology, and the American Urological Association, men with early prostate cancer who choose external beam radiation therapy (RT) and who do not need nodal irradiation should be offered moderate hypofractionated (eg, 60 Gy in 20 fractions or 70 Gy in 28 fractions) rather than conventional fractionation RT (eg, 78 Gy in 39 fractions). Men should be counseled about the small increased risk of early gastrointestinal (GI) toxicity associated with this approach and the limited information on late GI and genitourinary toxicity beyond five years. Stereotactic body RT (ultrahypofractionation RT, eg, 42.7 Gy in seven fractions over 2.5 weeks) is an acceptable alternative for men with low- or intermediate-risk disease who do not need nodal irradiation, but not for high-risk disease.

Back to Top | Article Outline

Maintenance Olaparib in BRCA-Associated Advanced Ovarian Cancer

The role of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in advanced epithelial ovarian cancer (EOC) is under active investigation, particularly for those with BRCA-associated cancers. In the randomized phase III SOLO1 trial, olaparib for maintenance treatment was compared with placebo in almost 400 women with an identified BRCA mutation, advanced high-grade serous or endometrioid cancer, and a response to frontline platinum-based chemotherapy. More than 99 percent of the women had germline BRCA mutations. At a follow-up of 41 months, olaparib improved the three-year rate of freedom from disease progression or death (60 versus 27 percent). Given these data, we suggest maintenance olaparib for BRCA mutation carriers with advanced EOC who respond to frontline platinum-based therapy. Additionally, some UpToDate experts suggest that women with advanced EOC who do not have a BRCA germline mutation undergo tumor assessment for somatic BRCA mutations, as patients with these cancers may also derive benefit from maintenance olaparib.

Disclaimer: This content is provided for reference purposes only and represents a portion of the UpToDate topic. You may not rely on the content or any information cited here as being applicable to specific patient circumstances. All topics are updated as new evidence becomes available and our peer review process is complete. Subscribe to www.uptodate.com for current content and recommendations.

Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!